<p>Nektar Therapeutics（纳斯达克股票代码：NKTR - 获取免费报告）于周四发布了季度财报。这家生物制药公司报告本季度每股收益为（$1.85），超出市场普遍预期的（$2.85）$1.00，FiscalAI 报道。Nektar Therapeutics 的净利润率为负 163.17%，股本回报率为负 631.43%。该公司本季度的收入为 1179 万美元，而市场普遍预期为 1020 万美元。</p>
<p>获取 <strong>Nektar Therapeutics</strong> 的提醒：</p>
<h2>Nektar Therapeutics 股票表现</h2>
<ul>
<li>3 只具有爆炸性增长趋势的看涨生物科技股票</li>
</ul>
<p>周五午盘交易中，NKTR 上涨了$0.85，达到了$55.97。该公司的交易量为 854,201 股，而其平均交易量为 906,206 股。该公司的市值为 10.6 亿美元，市盈率为-6.36，贝塔值为 1.19。该公司的 50 日简单移动平均线为$54.43，200 日简单移动平均线为$30.79。Nektar Therapeutics 的 12 个月低点为$6.45，12 个月高点为$66.92。</p>
<h2>内部人士下注</h2>
<p>在其他新闻中，首席执行官 Howard W. Robin 于 9 月 9 日星期二出售了 6,666 股公司的股票。股票以平均价格$46.69 出售，总交易额为$311,235.54。交易后，首席执行官持有 49,342 股公司的股票，价值$2,303,777.98。这代表着其持股比例减少了 11.90%。该出售在与 SEC 的法律文件中披露，相关信息可通过此链接获取。此外，内部人士 Jonathan Zalevsky 于 9 月 4 日星期四出售了 1,721 股公司的股票。股票以平均价格$33.52 出售，总交易额为$57,687.92。交易后，该内部人士持有 17,462 股公司的股票，价值约为$585,326.24。该交易使其持股比例减少了 8.97%。有关此次出售的更多细节可在官方 SEC 披露中找到。在过去 90 天内，内部人士已出售 25,178 股公司股票，价值$938,776。目前，5.25% 的股票由公司内部人士持有。</p>
<h2>机构资金流入和流出</h2>
<ul>
<li>生物科技催化剂警报：NKTR、CDTX 和 WGS 大幅上涨</li>
</ul>
<p>几家对冲基金和其他机构投资者最近买卖了该公司的股票。Vanguard Group Inc.在第三季度将其在 Nektar Therapeutics 的持股增加了 30.0%。Vanguard Group Inc.目前拥有 948,647 股这家生物制药公司的股票，价值$53,978,000，此前在上个季度又购买了 219,155 股。Envestnet Asset Management Inc.在第三季度获得了 Nektar Therapeutics 的新头寸，价值约为$574,000。Marshall Wace LLP 在第二季度购买了 Nektar Therapeutics 的新头寸，价值$367,000。Rhumbline Advisers 在第一季度将其在 Nektar Therapeutics 的持股增加了 23.3%。Rhumbline Advisers 目前拥有 221,761 股这家生物制药公司的股票，价值$151,000，此前在上个季度又购买了 41,948 股。最后，AQR Capital Management LLC 在第一季度将其在 Nektar Therapeutics 的持股增加了 336.9%。AQR Capital Management LLC 目前拥有 3,640,851 股这家生物制药公司的股票，价值$2,463,000，此前在上个季度又购买了 2,807,595 股。机构投资者目前持有该公司 75.88% 的股票。</p>
<h2>分析师评级变动</h2>
<p>多位分析师最近对该股票发布了报告。Weiss Ratings 在 10 月 8 日星期三的研究报告中重申了对 Nektar Therapeutics 股票的 “卖出（d-）” 评级。B. Riley 在 9 月 23 日星期二的研究报告中将 Nektar Therapeutics 的目标价格从$85.00 提高至$105.00，并给予该股票 “买入” 评级。Wall Street Zen 在周六的研究报告中将 Nektar Therapeutics 的评级从 “卖出” 上调至 “持有”。最后，BTIG Research 在 9 月 19 日星期五的报告中重申了 “买入” 评级，并设定了 Nektar Therapeutics 的目标价格为$100.00。五位分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat，该公司的平均评级为 “适度买入”，共识目标价格为$89.00。</p>
<ul>
<li>Nektar 因药物试验数据上涨 157%——还能更高吗？</li>
</ul>
<p><strong>查看我们对 Nektar Therapeutics 的最新股票分析</strong></p>
<h2>Nektar Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Nektar Therapeutics 是一家生物制药公司，专注于在美国和国际上发现和开发免疫疗法领域的药物。该公司正在开发 rezpegaldesleukin，这是一种细胞因子 Treg 刺激剂，目前正在进行针对系统性红斑狼疮和溃疡性结肠炎的二期临床试验，以及针对特应性皮炎和银屑病的二期 b 临床试验；以及 NKTR-255，一种 IL-15 受体激动剂，目前正在进行一期临床试验，以增强免疫系统对抗癌症的自然能力。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们更看好的股票超过 Nektar Therapeutics</li>
<li>你应该将这些沃伦·巴菲特的股票加入你的投资组合吗？</li>
<li>Rivian 的图表显示可以购买，但一些分析师仍然表示不建议购买</li>
<li>5 只值得考虑的高评级分红股票</li>
<li>e.l.f.的抛售是购买的好时机，分析师表示</li>
<li>投资者如何从盘后交易中受益</li>
<li>T-Mobile 是最被低估的大型股——是时候购买了吗？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TktUUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TktUUg"/></p>
<p><em>此即时新闻提醒是由叙述科学技术和 MarketBeat 的金融数据生成的，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 $1,000 在 Nektar Therapeutics 吗？</h2>
<p>在考虑 Nektar Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只股票，顶级分析师正在悄悄地向他们的客户推荐在更广泛的市场注意到之前购买……而 Nektar Therapeutics 并不在名单上。</p>
<p>虽然 Nektar Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

内克塔治疗

<p>内克塔治疗（NASDAQ:NKTR）公布了季度财报，每股收益（EPS）为（$1.85），超出预期的（$2.85）$1.00。公司收入为 1179 万美元，超过了 1020 万美元的预测。尽管净利润率为负的 163.17%，股本回报率为-631.43%，股票价格仍上涨至$55.97。内部交易包括首席执行官霍华德·W·罗宾出售股份，机构投资者持有 75.88% 的股份。分析师评级不一，普遍目标价为$89.00，平均评级为 “适度买入”</p>

<p>Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) issued its quarterly earnings results on Thursday. The biopharmaceutical company reported ($1.85) EPS for the quarter, beating the consensus estimate of ($2.85) by $1.00, FiscalAI reports. Nektar Therapeutics had a negative net margin of 163.17% and a negative return on equity of 631.43%. The business had revenue of $11.79 million during the quarter, compared to the consensus estimate of $10.20 million.</p>
<div class="lb-trans"><p>Nektar Therapeutics（纳斯达克股票代码：NKTR - 获取免费报告）于周四发布了季度财报。这家生物制药公司报告本季度每股收益为（$1.85），超出市场普遍预期的（$2.85）$1.00，FiscalAI 报道。Nektar Therapeutics 的净利润率为负 163.17%，股本回报率为负 631.43%。该公司本季度的收入为 1179 万美元，而市场普遍预期为 1020 万美元。</p>
</div><p>Get <strong>Nektar Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Nektar Therapeutics</strong> 的提醒：</p>
</div><h2>Nektar Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Nektar Therapeutics 股票表现</h2>
</div><ul>
<li>3 Bullish Biotech Stocks With Explosive Growth Trends</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只具有爆炸性增长趋势的看涨生物科技股票</li>
</ul>
</div><p>NKTR traded up $0.85 during midday trading on Friday, hitting $55.97. The company had a trading volume of 854,201 shares, compared to its average volume of 906,206. The company has a market capitalization of $1.06 billion, a PE ratio of -6.36 and a beta of 1.19. The firm's 50-day simple moving average is $54.43 and its 200-day simple moving average is $30.79. Nektar Therapeutics has a twelve month low of $6.45 and a twelve month high of $66.92.</p>
<div class="lb-trans"><p>周五午盘交易中，NKTR 上涨了$0.85，达到了$55.97。该公司的交易量为 854,201 股，而其平均交易量为 906,206 股。该公司的市值为 10.6 亿美元，市盈率为-6.36，贝塔值为 1.19。该公司的 50 日简单移动平均线为$54.43，200 日简单移动平均线为$30.79。Nektar Therapeutics 的 12 个月低点为$6.45，12 个月高点为$66.92。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other news, CEO Howard W. Robin sold 6,666 shares of the company's stock in a transaction on Tuesday, September 9th. The stock was sold at an average price of $46.69, for a total transaction of $311,235.54. Following the transaction, the chief executive officer owned 49,342 shares of the company's stock, valued at $2,303,777.98. This represents a 11.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Jonathan Zalevsky sold 1,721 shares of the company's stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $33.52, for a total transaction of $57,687.92. Following the transaction, the insider owned 17,462 shares in the company, valued at approximately $585,326.24. The trade was a 8.97% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 25,178 shares of company stock valued at $938,776. 5.25% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他新闻中，首席执行官 Howard W. Robin 于 9 月 9 日星期二出售了 6,666 股公司的股票。股票以平均价格$46.69 出售，总交易额为$311,235.54。交易后，首席执行官持有 49,342 股公司的股票，价值$2,303,777.98。这代表着其持股比例减少了 11.90%。该出售在与 SEC 的法律文件中披露，相关信息可通过此链接获取。此外，内部人士 Jonathan Zalevsky 于 9 月 4 日星期四出售了 1,721 股公司的股票。股票以平均价格$33.52 出售，总交易额为$57,687.92。交易后，该内部人士持有 17,462 股公司的股票，价值约为$585,326.24。该交易使其持股比例减少了 8.97%。有关此次出售的更多细节可在官方 SEC 披露中找到。在过去 90 天内，内部人士已出售 25,178 股公司股票，价值$938,776。目前，5.25% 的股票由公司内部人士持有。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><ul>
<li>Biotech Catalyst Alert: NKTR, CDTX &amp; WGS Rallying With Big Gains</li>
</ul>
<div class="lb-trans"><ul>
<li>生物科技催化剂警报：NKTR、CDTX 和 WGS 大幅上涨</li>
</ul>
</div><p>Several hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in shares of Nektar Therapeutics by 30.0% during the third quarter. Vanguard Group Inc. now owns 948,647 shares of the biopharmaceutical company's stock worth $53,978,000 after purchasing an additional 219,155 shares in the last quarter. Envestnet Asset Management Inc. acquired a new position in Nektar Therapeutics during the 3rd quarter worth approximately $574,000. Marshall Wace LLP bought a new position in Nektar Therapeutics in the second quarter valued at $367,000. Rhumbline Advisers increased its position in shares of Nektar Therapeutics by 23.3% in the first quarter. Rhumbline Advisers now owns 221,761 shares of the biopharmaceutical company's stock valued at $151,000 after acquiring an additional 41,948 shares during the last quarter. Finally, AQR Capital Management LLC raised its stake in shares of Nektar Therapeutics by 336.9% during the 1st quarter. AQR Capital Management LLC now owns 3,640,851 shares of the biopharmaceutical company's stock worth $2,463,000 after purchasing an additional 2,807,595 shares in the last quarter. Institutional investors own 75.88% of the company's stock.</p>
<div class="lb-trans"><p>几家对冲基金和其他机构投资者最近买卖了该公司的股票。Vanguard Group Inc.在第三季度将其在 Nektar Therapeutics 的持股增加了 30.0%。Vanguard Group Inc.目前拥有 948,647 股这家生物制药公司的股票，价值$53,978,000，此前在上个季度又购买了 219,155 股。Envestnet Asset Management Inc.在第三季度获得了 Nektar Therapeutics 的新头寸，价值约为$574,000。Marshall Wace LLP 在第二季度购买了 Nektar Therapeutics 的新头寸，价值$367,000。Rhumbline Advisers 在第一季度将其在 Nektar Therapeutics 的持股增加了 23.3%。Rhumbline Advisers 目前拥有 221,761 股这家生物制药公司的股票，价值$151,000，此前在上个季度又购买了 41,948 股。最后，AQR Capital Management LLC 在第一季度将其在 Nektar Therapeutics 的持股增加了 336.9%。AQR Capital Management LLC 目前拥有 3,640,851 股这家生物制药公司的股票，价值$2,463,000，此前在上个季度又购买了 2,807,595 股。机构投资者目前持有该公司 75.88% 的股票。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>A number of analysts have recently issued reports on the stock. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Nektar Therapeutics in a research report on Wednesday, October 8th. B. Riley boosted their target price on shares of Nektar Therapeutics from $85.00 to $105.00 and gave the stock a &#34;buy&#34; rating in a research report on Tuesday, September 23rd. Wall Street Zen raised shares of Nektar Therapeutics from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Saturday. Finally, BTIG Research reissued a &#34;buy&#34; rating and set a $100.00 price objective on shares of Nektar Therapeutics in a report on Friday, September 19th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $89.00.</p>
<div class="lb-trans"><p>多位分析师最近对该股票发布了报告。Weiss Ratings 在 10 月 8 日星期三的研究报告中重申了对 Nektar Therapeutics 股票的 “卖出（d-）” 评级。B. Riley 在 9 月 23 日星期二的研究报告中将 Nektar Therapeutics 的目标价格从$85.00 提高至$105.00，并给予该股票 “买入” 评级。Wall Street Zen 在周六的研究报告中将 Nektar Therapeutics 的评级从 “卖出” 上调至 “持有”。最后，BTIG Research 在 9 月 19 日星期五的报告中重申了 “买入” 评级，并设定了 Nektar Therapeutics 的目标价格为$100.00。五位分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat，该公司的平均评级为 “适度买入”，共识目标价格为$89.00。</p>
</div><ul>
<li>Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?</li>
</ul>
<div class="lb-trans"><ul>
<li>Nektar 因药物试验数据上涨 157%——还能更高吗？</li>
</ul>
</div><p><strong>View Our Latest Stock Analysis on Nektar Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Nektar Therapeutics 的最新股票分析</strong></p>
</div><h2>Nektar Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Nektar Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.</p>
<div class="lb-trans"><p>Nektar Therapeutics 是一家生物制药公司，专注于在美国和国际上发现和开发免疫疗法领域的药物。该公司正在开发 rezpegaldesleukin，这是一种细胞因子 Treg 刺激剂，目前正在进行针对系统性红斑狼疮和溃疡性结肠炎的二期临床试验，以及针对特应性皮炎和银屑病的二期 b 临床试验；以及 NKTR-255，一种 IL-15 受体激动剂，目前正在进行一期临床试验，以增强免疫系统对抗癌症的自然能力。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Nektar Therapeutics</li>
<li>Should You Add These Warren Buffett Stocks to Your Portfolio?</li>
<li>Rivian’s Chart Says Go, But Some Analysts Still Say No</li>
<li>5 Top Rated Dividend Stocks to Consider</li>
<li>e.l.f. Sell-Off Is a Good Time to Buy, According to Analysts</li>
<li>How Can Investors Benefit From After-Hours Trading</li>
<li>T-Mobile Is The Most Oversold Mega-Cap Stock—Time to Buy?</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 Nektar Therapeutics</li>
<li>你应该将这些沃伦·巴菲特的股票加入你的投资组合吗？</li>
<li>Rivian 的图表显示可以购买，但一些分析师仍然表示不建议购买</li>
<li>5 只值得考虑的高评级分红股票</li>
<li>e.l.f.的抛售是购买的好时机，分析师表示</li>
<li>投资者如何从盘后交易中受益</li>
<li>T-Mobile 是最被低估的大型股——是时候购买了吗？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TktUUg" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=NKTR"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒是由叙述科学技术和 MarketBeat 的金融数据生成的，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Nektar Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 在 Nektar Therapeutics 吗？</h2>
</div><p>Before you consider Nektar Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Nektar Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nektar Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只股票，顶级分析师正在悄悄地向他们的客户推荐在更广泛的市场注意到之前购买……而 Nektar Therapeutics 并不在名单上。</p>
</div><p>While Nektar Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Nektar Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

内克塔治疗公司（NASDAQ:NKTR）公布了财报，每股收益超出预期 1.00 美元